These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18519814)

  • 21. Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity.
    Ho SK; Xu Z; Thakur A; Fox M; Tan SS; DiGiammarino E; Zhou L; Sho M; Cairns B; Zhao V; Xiong M; Samayoa J; Forsyth CM; Powers DB; Chao DT; Hollenbaugh D; Alvarez HM; Akamatsu Y
    Mol Cancer Ther; 2020 Apr; 19(4):1040-1051. PubMed ID: 31974274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
    Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
    Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.
    Yonezawa A; Dutt S; Chester C; Kim J; Kohrt HE
    Clin Cancer Res; 2015 Jul; 21(14):3113-20. PubMed ID: 25908780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting peripheral blood pro-inflammatory cytotoxic lymphocytes by inhibiting CD137 expression: novel potential treatment for COPD.
    Hodge G; Holmes M; Jersmann H; Reynolds PN; Hodge S
    BMC Pulm Med; 2014 May; 14():85. PubMed ID: 24885856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates.
    Gao Y; Yang T; Liu H; Song N; Dai C; Ding Y
    FEBS Open Bio; 2022 Dec; 12(12):2166-2178. PubMed ID: 36176235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
    Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
    J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
    Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
    Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking.
    Turaj AH; Cox KL; Penfold CA; French RR; Mockridge CI; Willoughby JE; Tutt AL; Griffiths J; Johnson PWM; Glennie MJ; Levy R; Cragg MS; Lim SH
    Sci Rep; 2018 Feb; 8(1):2278. PubMed ID: 29396470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab.
    Yonezawa A; Chester C; Rajasekaran N; Kohrt HE
    Chin Clin Oncol; 2016 Feb; 5(1):5. PubMed ID: 26932429
    [No Abstract]   [Full Text] [Related]  

  • 30. CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function.
    Cabo M; Santana-Hernández S; Costa-Garcia M; Rea A; Lozano-Rodríguez R; Ataya M; Balaguer F; Juan M; Ochoa MC; Menéndez S; Comerma L; Rovira A; Berraondo P; Albanell J; Melero I; López-Botet M; Muntasell A
    Cancer Immunol Res; 2021 Dec; 9(12):1476-1490. PubMed ID: 34580116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of cloned human natural killer cells via Fc gamma RIII.
    Werfel T; Uciechowski P; Tetteroo PA; Kurrle R; Deicher H; Schmidt RE
    J Immunol; 1989 Feb; 142(4):1102-6. PubMed ID: 2464637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation.
    Kim DH; Chang WS; Lee YS; Lee KA; Kim YK; Kwon BS; Kang CY
    J Immunol; 2008 Feb; 180(4):2062-8. PubMed ID: 18250411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.
    Enell Smith K; Fritzell S; Nilsson A; Barchan K; Rosén A; Schultz L; Varas L; Säll A; Rose N; Håkansson M; von Schantz L; Ellmark P
    Cancer Immunol Immunother; 2023 Dec; 72(12):4145-4159. PubMed ID: 37796298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.
    Gauttier V; Judor JP; Le Guen V; Cany J; Ferry N; Conchon S
    Int J Cancer; 2014 Dec; 135(12):2857-67. PubMed ID: 24789574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD137 (4-1BB) Engagement Fine-Tunes Synergistic IL-15- and IL-21-Driven NK Cell Proliferation.
    Vidard L; Dureuil C; Baudhuin J; Vescovi L; Durand L; Sierra V; Parmantier E
    J Immunol; 2019 Aug; 203(3):676-685. PubMed ID: 31201235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses.
    Hong JP; Reynoso GV; Andhey PS; Swain A; Turner JS; Boon ACM; Krammer F; Ellebedy AH; Zanini F; Artyomov M; Hickman HD; Diamond MS
    Cell Rep Med; 2020 Jun; 1(3):. PubMed ID: 32699843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor cells of non-hematopoietic and hematopoietic origins express activation-induced C-type lectin, the ligand for killer cell lectin-like receptor F1.
    Akatsuka A; Ito M; Yamauchi C; Ochiai A; Yamamoto K; Matsumoto N
    Int Immunol; 2010 Sep; 22(9):783-90. PubMed ID: 20663776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic vaccination with tumor cells that engage CD137.
    Hellstrom KE; Hellstrom I
    J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy.
    Makkouk A; Sundaram V; Chester C; Chang S; Colevas AD; Sunwoo JB; Maecker H; Desai M; Kohrt HE
    Ann Oncol; 2017 Feb; 28(2):415-420. PubMed ID: 27831501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.
    Koerner SP; André MC; Leibold JS; Kousis PC; Kübler A; Pal M; Haen SP; Bühring HJ; Grosse-Hovest L; Jung G; Salih HR
    Leukemia; 2017 Feb; 31(2):459-469. PubMed ID: 27435001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.